Efficacy of Lifestyle Changes in Subjects with Non-Alcoholic Liver Steatosis and Metabolic Syndrome May Be Improved with an Antioxidant Nutraceutical: A Controlled Clinical Study

Drugs in R and D

Volumn 15, Issue 1, 2015, Pages 21-25

  Sorrentino, Gianpaolo ^a   Crispino, Paola ^b   Coppola, Daniela ^b   De Stefano, Giorgio ^b  

^a Clinic Center   (Italy)

^b Interventional Unit Ultrasound   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL DERIVATIVE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; EUROSIL 85; NUTRACEUTICAL; SILYMARIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ALPHA TOCOPHEROL; DRUG COMBINATION;

ABDOMINAL CIRCUMFERENCE; ADULT; ARTICLE; BIOMETRY; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DRUG EFFICACY; ECHOGRAPHY; EXERCISE; FEMALE; HUMAN; LIFESTYLE MODIFICATION; LIPID ACCUMULATION PRODUCT INDEX; LIVER LOBE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; AGED; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG COMBINATION; LIFESTYLE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIOXIDANTS; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; DRUG COMBINATIONS; FEMALE; HUMANS; LIFE STYLE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; SILYMARIN; TREATMENT OUTCOME; VITAMIN E;

EID: 84925501272     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-015-0084-x     Document Type: Article

References (31)

1. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17(Suppl.):S186–90.
2. Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver. Epidemiology and natural history. Rev Recent Clin Trials. 2014;9(3):126–33.
3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2012;55(6):2005–23.
4. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112–7.
5. Bedogni G, Bellentani S. Fatty liver: how frequent is it and why? Ann Hepatol. 2004;3(2):63–5.
6. Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology. 2007;46:1387–91.
7. Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol. 2004;16:1087–93.
8. Marchesini G, Brizi M, Bianchi G, et al. NAFLD: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–50.
9. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183–92.
10. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332(6037):1519–23.
11. LaBrecque D, et al. World Gastroenterology Organisation global guidelines: NAFLD and NASH. Milwaukee: World Gastroenterology Organisation; 2012.
12. Tiniakos DG, Vos MB, Brunt EM. NAFLD: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145–71.
13. Targher G, Day CO, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–50.
14. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–50.
15. Promrat K, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–9.
16. Centis E, Moscatiello S, Bugianesi E, et al. Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. J Hepatol. 2013;58:771–7.
17. Velussi M, Cerniogoi AM, De Monte A, et al. Long-term treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997;26:871–9.
18. Huseini HF. The efficacy of Silybum marianun (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled clinical trial. Phytother Res. 2006;20:1036–9.
19. Hussain SA. Silymarin as an adjunct to glybenclamide therapy includes long-term and postprandial glycemic control and body mass index in type II diabetes. J Med Food. 2007;10(3):543–7.
20. Loguercio C, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med. 2012;52(9):1658–65.
21. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–85.
22. Italian Society of Ultrasonography in Medicine and Biology (SIUMB). Trattato italiano di ecografia. Vermezzo: Poletto Editore; 1995.
23. Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol. 2014;20(45):16831–40.
24. Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–8.
25. Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol. 2010;10:98.
26. Trovato FM, Catalano D, Martines GF, et al. Mediterranean diet and non-alcoholic fatty liver disease: the need for extended and comprehensive interventions. Clin Nutr. 2015;34(1):86–8.
27. Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40(10):1209–22.
28. Cuthbertson DJ, Weickert MO, Lythgoe D, et al. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur J Endocrinol. 2014;171(5):561–9.
29. Hawke RL, Schrieber SJ, Soule TA, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010;50(4):434–49.
30. Trappoliere M, Caligiuri A, Schmid M, et al. Silybinin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol. 2009;50(6):1102–11.
31. Kim M, Yang SG, Kim JM, et al. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis. Int J Mol Med. 2012;30:473–9.